Mount Sinai, LabCorp, and Philips announced they are collaborating to establish the Mount Sinai Digital and Artificial Intelligence (AI)-Enabled Pathology Center of Excellence. The new center will feature the Philips IntelliSite Pathology Solution, the first digital pathology system FDA approved for primary diagnostic use, which will help the organizations enhance the quality and lower the costs of patient care.
Role of LabCorp
LabCorp will lead the integration of Philips’ system at Mount Sinai, leveraging its previous expertise with the digital pathology technology, which it will implemented in four of its laboratories back in 2018. Initially, Philips’ system will be used at Mount Sinai for interpretations of genitourinary malignancies, mainly prostate tumors, as well as cancers of the head and neck. The technology will allow Mount Sinai to expand its digital pathology capabilities for primary diagnosis and consultations across the Mount Sinai system, improving collaboration among pathologists and making it easier to provide expert diagnostic opinions in complex cases.
“LabCorp and Mount Sinai continue to focus on innovations to enhance the quality and lower the costs of patient care, and we’re pleased to introduce digital pathology to Mount Sinai as the next phase of our collaboration,” said William B. Haas, senior vice president of LabCorp Diagnostics’ Northeast Division. “We’ve taken significant steps to enhance laboratory services across the Mount Sinai system since early 2017, and we look forward to continuing to build on those successes to advance LabCorp’s mission and our shared goal to improve health and improve lives.”
Center of Excellence Location
The Center of Excellence will be housed within Mount Sinai’s Department of Pathology, Molecular and Cell-Based Medicine and will use the Philips IntelliSite Pathology Solution to expand digital pathology capabilities for primary diagnosis and consultations across the Mount Sinai system. The department processes more than 80 million diagnostic tests a year, making it one of the largest academic departments of its kind in the country.
Deployment of Philips IntelliSite Pathology Solution Across Enterprise
The Center of Excellence will include the deployment of the Philips IntelliSite Pathology Solution at each of Mount Sinai’s eight hospitals and select ambulatory care locations. Digital pathology will allow for real-time pathology interpretations for physicians and patients throughout the New York metropolitan area without requiring the pathologist to be on-site where the patient is receiving care. Mount Sinai participated in Philips’ digital pathology performance evaluation to obtain market clearance in the U.S., gaining valuable expertise with the research version of the digital pathology system, providing the foundation for Mount Sinai’s AI diagnostic test development. Implementation of the clinical Philips IntelliSite Pathology Solution is underway and Mount Sinai expects to begin its use in the next several months.
Why It Matters
“Digital pathology gives us the unprecedented opportunity to expand our services to the community at large, and engage members of our department, considered key opinion leaders in their field, to provide expert diagnostic opinions in complex cases. This, in addition to our new predictive AI-based tests, introduces the potential for optimization of treatment efficacy, and provides the opportunity for improved clinical outcomes,” said Carlos Cordon-Cardo, M.D., Ph.D., chairman of the Department of Pathology, Molecular and Cell-Based Medicine at Mount Sinai Health System and professor of Pathology, Genetics and Genomic Sciences, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai.
